Q2 2026 Inspire Medical Systems Inc Earnings Call Transcript
Key Points
- Inspire Medical Systems Inc (INSP) delivered second-quarter results ahead of expectations, with revenue of $200.6 million and improved profitability despite coding and reimbursement headwinds.
- The company is increasing its 2026 full-year outlook for revenue, adjusted operating margin, and adjusted earnings per share, reflecting confidence in its strategic initiatives.
- CMS has proposed a 12% increase in hospital outpatient reimbursement and a 15% increase in ASC reimbursement for the Inspire 5 procedure in 2027, which could boost future revenue.
- The launch of Project Horizon is expected to create $30 million in annualized growth investment capacity, which will be reinvested into patient access and education initiatives to accelerate growth.
- Strong clinical data, including the full results of the INSPIRE-5 trial and publications on hypoxic burden and cardiovascular outcomes, support the therapy's long-term benefits and market differentiation.
- The company is seeing improved trends in prior authorization submissions and coding clarity, indicating that the reimbursement disruption is being effectively managed.
- International revenue saw a strong step-up in Q2, driven by growth in continental Europe, France, and other markets, diversifying revenue streams.
- Revenue decreased 7.6% year-over-year in Q2 2026, primarily due to the ongoing impact of coding and reimbursement disruption, including a decline in preauthorizations.
- The company estimates a total adverse impact of $120 million to $130 million from coding and reimbursement challenges and the WISER program for the full year 2026.
- Two Medicare Administrative Contractors (MACs) require a Dash-52 modifier for Inspire 5 procedures, leading to payment reductions ranging from 0% to 30% of the national average Medicare payment.
- The proposed 2027 physician fee schedule includes a 4% decrease in reimbursement for CPT code 64582, which could impact physician adoption.
- The company's revised application for a new Category 1 CPT code was not approved in April, and approval is not expected until at least September, with implementation potentially delayed to 2028.
- Project Horizon will incur $20 million to $25 million in pre-tax restructuring charges, with 90% expected in Q3, impacting near-term profitability.
- The company forecasts a year-over-year revenue decline of 8% to 10% in Q3 2026, indicating continued pressure from the reimbursement environment.
Thank you. Good afternoon. My name is Dilem and I'll be your conference operator today. this time, I'd like to welcome everyone to the Inspire Medical System second quarter 2026 conference call. All lines have been placed on mute to prevent any background noise.
After the speaker's remarks, there will be a question and answer session. I'll now hand the call over to your first speaker, Eski Yaja, the Vice President of Investor Relations at Inspire. You may begin the conference.
Thank you, Dilem, and thank you all for participating in today's call. Joining me are Tim Herbert, Chairman and Chief Executive Officer, and Matt Osberg, Chief Financial Officer. Earlier today, we released financial results for the three months ended June 30, 2026. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meaning of the federal securities laws.
all forward-looking statements, including, without limitation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
